Marisa Wexler, MS, senior science writer —

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. A…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. The total economic…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. People…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. Sativex…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. People with …

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference.

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the…

Treatment with hydroxychloroquine, an anti-malaria medication, appeared to help slow disability progression among people with primary-progressive multiple sclerosis (PPMS) in a small, proof-of-concept clinical trial. Hydroxychloroquine “is a promising treatment candidate for PPMS and should be investigated further in randomized controlled clinical trials,” its researchers wrote. Results of the study…

Treatment with evobrutinib, an experimental therapy for relapsing forms of multiple sclerosis (MS), reduced the size of inflammation-associated brain lesions in a Phase 2 clinical trial, data show. The oral medication was also found to be generally safe and well tolerated, according to an analysis of trial data in…

Increasing the activity of a gene called Myc can make oligodendrocyte precursor cells, or the cells that repair myelin, more efficient — “ground-breaking research” that could have implications for advancing MS treatments, according to a new study by Cambridge researchers. The study, “Myc determines the functional age…

An upcoming conference focused on progressive multiple sclerosis (MS) will offer the latest insights about the underlying biology of the disease, and treatment and clinical strategies in development. The one-day conference, “Emerging Research & Trial Strategies for Progressive Multiple Sclerosis,” is taking place virtually on Oct. 4,and is…

Cognitive rehabilitation is an effective therapy for cognitive problems brought on by multiple sclerosis (MS), a review study highlights. “Clinicians should consider this low-cost, low-risk, yet effective treatment approach for their patients,” its researchers wrote. The study, “Neurological update: cognitive rehabilitation in multiple sclerosis,” was published…

The therapeutic administration of mesenchymal stem cells can improve functional abilities and promote the restoration of lost myelin in rodent models of multiple sclerosis (MS), according to a new analysis of published studies. The findings highlight the potential of these stem cells, but also point to a need for…

In an unexpected discovery, scientists working to understand the biological underpinnings of brain tumors found that increasing the activity of a protein receptor called PDGFRA reduces the production of myelin — the fatty coating that is lost in multiple sclerosis (MS) — in the nervous system. “We saw that…

The presence of a light-sensing protein in the brain during the early stages of fetal development may help to explain why certain neurological diseases, like multiple sclerosis (MS), are more common among people born at specific times of the year, a study found. The researchers, who noted that people…

First-line treatment with Tecfidera (dimethyl fumarate) leads to a lower rate of relapses in people with relapsing-remitting multiple sclerosis (RRMS) than does treatment with Aubagio (teriflunomide) or injectable immunomodulators, according to an analysis of insurance data from France. “These data will be useful to feed into physician…

People who develop colon cancer are more likely to die in the first year, from that cancer or other causes, if they also have multiple sclerosis (MS), a new study indicates. MS disability seems to contribute to this association. “These results warrant further investigation to determine what factors may…

Anti-CD20 antibody therapies that target B-cells are highly effective for reducing the risk of relapses in people with relapsing-remitting multiple sclerosis (RRMS), a new analysis confirms. The analysis did not find any significant differences in efficacy or safety among the anti-CD20 therapies currently approved to treat RRMS, though…

Treatment with fesoterodine fumarate — which comes as an extended-release tablet patients can take by mouth — can reduce bladder pressure and improve quality of life in people with bladder impairments due to multiple sclerosis (MS) or spinal cord injuries, new research shows. “A 3‐…

A committee of the European Medicines Agency is recommending that Vumerity (diroximel fumarate) be approved as an oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS) in the European Union. The opinion, from the agency’s Committee for Medicinal Products for Human Use (CHMP), will now be sent…

While people with multiple sclerosis (MS) taking anti-CD20 therapies do not mount a robust antibody response after getting vaccinated against COVID-19, the vaccines do strongly activate other parts of the immune system that are likely to be helpful in fighting the virus, a new study shows. “The message…

An imaging feature called a rim lesion is found in about 4 out of every 10 people with multiple sclerosis (MS), according to a review study. These rims, thought to represent areas of chronic brain inflammation in which myelin is being progressively damaged, may serve as alternate biomarkers of…

A class of molecules called positive allosteric modulators, or PAMs, may be useful in treating pain caused by nerve damage — a common symptom of multiple sclerosis (MS) — according to a new study that sheds light on how these molecules work. The international team of researchers behind…

An interaction between immune cells and glia cells in the brain, mediated by the C1q complement system protein, appears to drive chronic inflammation in multiple sclerosis (MS), new research shows. Inhibiting this protein helped to resolve inflammation in mouse models of MS and in tissue cultures, its researchers found.

Getting the Pfizer-BioNTech vaccine for COVID-19 does not increase the risk of multiple sclerosis (MS) relapses in the two months following vaccination, according to a new study. The results support recommending COVID-19 vaccines for people with MS, its researchers said. “The incidence of relapses in the 2 months before and…

Experiencing serious infections during adolescence is tied to an increased risk of developing multiple sclerosis (MS) later in life, but those occurring in childhood don’t increase MS risk, according to a new Swedish study. The study also found that certain types of infections, especially those that affect the central…

People with relapsing-remitting multiple sclerosis (RRMS) in Sweden have lower rates of worsening disability than those who live in Denmark, likely due to differences in treatment strategies in each country, according to a new study. “This study shows that, for the first time to our knowledge, differences in national…

Most people with multiple sclerosis (MS) in the U.S. have health insurance, but many lack important other types of insurance, such as life insurance, short-term disability insurance, and long-term care insurance, according to an online survey of patients. Its findings suggest that MS patients who are likely to be…

A new research project, funded by the National Institutes of Health (NIH), aims to better understand how different types of cells in the nervous system — specifically neurons and glia cells — communicate with each other and ultimately affect both motor and non-motor functions. Its findings may have important implications…